Search Results 311-320 of 17311 for SC
SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...
Fei-Zhang DJ, Lutfallah SC, Mensah J, Chelius DC, Ruff MW, Dixit K, Paludo J, Smith SS, Patel UA, D'Souza JN, Rastatter JC, Sheyn AM.
Camilleri, Michael M.D., D.Sc. camilleri.michael@mayo.edu; Professor of Medicine; Professor of Pharmacology; Professor of Physiology · Chini, Eduardo N. M.D., Ph ...
Epub 1900 Jan 01. Karon BS, Meeusen JW, Bryant SC. Impact of Glucose Meter Error on Glycemic Variability and Time in Target Range During Glycemic Control After ...
The purpose of this study is to determine the safety of sc-rAAV2.5IL-1Ra, a gene therapy carried by a virus and delivered by injection into the knee joint of ...
The primary objective for PART 1 of this study is to demonstrate that treatment with semaglutide s.c. 2.4 mg improves liver histology compared to placebo in ...
At least one 4-week induction regimen of adalimumab (one 160 mg subcutaneous [SC] dose at Baseline, followed by one 80 mg SC dose at Week 2 [or one 80 mg SC ...
AlHilli MM, Bakkum-Gamez JN, Mariani A, Weaver AL, McGree ME, Keeney GL, Jatoi A, Dowdy SC, Podratz KC. Risk-adjusted outcomes in elderly endometrial cancer ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!